Efficacy was evaluated in 983 patients who met the following criteria^1,2:

• Aged 16–35 years at enrollment
• BMI <30 kg/m²
• Had ≥1 efficacy evaluable cycle

This study resulted in 9105 evaluable cycles at risk of pregnancy.¹

Primary endpoint^1,2

Pearl Index (pregnancies per 100 woman-years of use).

Based on on-treatment pregnancies with an estimated date of conception from first patch application through 7 days after last patch removal.

Secondary safety endpoints²

• Incidence of adverse events and serious adverse events
• Incidence of application site reactions
• Proportion of participants reporting scheduled and unscheduled bleeding
• Adhesion performance as measured by adhesion scores